Loading...
XSHE
002082
Market cap1.07bUSD
Dec 05, Last price  
12.42CNY
1D
-1.51%
1Q
25.96%
IPO
36.78%
Name

Wepon Pharmaceutical Holding Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002082 chart
P/E
137.03
P/S
5.26
EPS
0.09
Div Yield, %
0.64%
Shrs. gr., 5y
20.78%
Rev. gr., 5y
-38.03%
Revenues
1.44b
-6.39%
1,172,649,9013,738,956,3484,891,602,0035,835,868,4796,347,707,4308,053,707,36010,873,866,11210,972,922,38011,786,336,48811,451,694,09311,572,197,7729,183,466,30714,635,458,22314,335,310,46815,794,900,82113,701,855,5831,930,601,8661,786,428,3081,541,938,5841,443,365,223
Net income
55m
+12.66%
21,383,38632,849,65963,613,86774,047,353121,048,269151,985,726158,644,10586,409,313111,557,566107,530,80863,024,59769,735,58898,213,44884,080,466157,029,488284,935,733166,509,67774,322,52749,208,88355,440,971
CFO
120m
P
11,227,3923,500,56612,453,463253,062,50668,134,391162,264,5910202,732,245234,352,539140,310,21416,762,923310,712,8490135,396,1000151,006,12022,085,1880-72,869,795120,221,961
Dividend
Jul 11, 20240.08 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research, development, production, and sale of Chinese medicines, APIs, and preparations. It also develops medical devices, including orthopaedic implant devices, medical equipment, and protective equipment, as well as disposable bacteria medical polymer consumables; and provides hospital engineering services. The company was formerly known as Wanbangde New Building Materials Co., Ltd. and changed its name to Wanbangde Pharmaceutical Holding Group Co., Ltd. in April 2020. Wanbangde Pharmaceutical Holding Group Co., Ltd. was founded in 1985 and is based in Taizhou, China.
IPO date
Nov 20, 2006
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT